The expansion of India's QR code-based drug traceability framework to vaccines, antimicrobials, and anti-cancer drugs represents a paradigm shift in pharmaceutical governance. Critically examine the policy rationale, implementation challenges, and public health implications.

India, the "pharmacy of the world", has long battled spurious and sub-standard medicines. The June 2026 notification extending Schedule H2 QR/bar-code traceability under the Drugs Rules, 1945 to vaccines, antimicrobials, anti-cancer and narcotic drugs signals a genuine, if incremental, shift toward a digitally verifiable supply chain [1].

Policy rationale

• Anti-counterfeiting: unit-level QR enables end-to-end tracing (manufacturer→patient) and patient-side authentication via a software application [1].
• Phased continuity: builds on APIs (2022) and the top-300 brands mandate (G.S.R. 823(E), effective Aug 2023) — administrative realism, not a leap [2].
• AMR containment: tracing antimicrobials curbs irrational and grey-market dispensing, a WHO priority.

Implementation challenges

• Digital divide: rural chemists and patients often lack smartphones or reader access.
• Compliance cost burdens MSME manufacturers lacking serialisation infrastructure.
• Authentication is meaningless without an integrated central repository.
• Field enforcement rests with state drug controllers (Concurrent List) — capacity gaps persist.
• Staggered timelines (antimicrobials only from 2028) dilute urgency [1].

Public health implications

• Shields UIP vaccines and high-cost oncology drugs from life-threatening fakes.
• NDPS traceability [3] curbs diversion for abuse, but must not deny palliative-care access.
• Enables rapid batch recall and pharmacovigilance.

The framework is a welcome move from prescription control toward digital assurance. Its promise hinges on pairing mandates with reader infrastructure, a central database and MSME support — advancing SDG-3 and the right to safe medicines.